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Abstract 
 
The integrin αIIbβ3 on resting platelets can bind to immobilized fibrinogen resulting in 
platelet spreading and activation but requires activation to bind to soluble fibrinogen. 
αIIbβ3 is known to interact with the general integrin-recognition motif RGD (arginine–
glycine–aspartate) as well as the fibrinogen-specific γ-chain dodecapeptide; however 
it is not known how fibrinogen binding triggers platelet activation. NGR (asparagine–
glycine–arginine) is another integrin-recognition sequence present in fibrinogen and 
this study aims to determine if it plays a role in the interaction between fibrinogen and 
αIIbβ3. NGR-containing peptides inhibited resting platelet adhesion to fibrinogen with 
an IC50 of 175 µM but failed to inhibit the adhesion of activated platelets to 
fibrinogen (IC50 > 500 µM). Resting platelet adhesion to mutant fibrinogens lacking 
the NGR sequences was reduced compared to normal fibrinogen under both static and 
shear conditions (200 s-1). However, pre-activated platelets were able to fully spread 
on all types of fibrinogen. Thus, the NGR motif in fibrinogen is the site that is 
primarily responsible for the interaction with resting αIIbβ3 and is responsible for 
triggering platelet activation.  
 
Keywords. Platelets, GPIIb-IIIa, fibrinogen, platelet activation
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Introduction 
 
Platelets are anucleate cell bodies circulating in the blood stream and play a key role 
in hemostasis (1). Upon vascular injury they are recruited to the site of damage to 
prevent blood loss and to initiate healing. However, inappropriate platelet aggregation 
can occlude the vessel leading to stroke or myocardial infarction (2).  
 
The integrin αIIbβ3 is the platelet fibrinogen receptor and plays a key role in mediating 
platelet aggregation and subsequent thrombus formation (3). Like many integrins its 
ability to bind to ligands is controlled by its activation state (4). Platelet activation by 
agonists such as collagen, ADP or thrombin leads to activation of αIIbβ3 in a process 
known as inside-out signaling (5) resulting in a conformational change in the integrin 
allowing it to bind to soluble fibrinogen (6). However, if fibrinogen is immobilized 
first it can support resting platelet adhesion, which leads to platelet activation in a 
process known as outside-in signaling (7, 8). It is not known why resting αIIbβ3 binds 
to immobilized fibrinogen but not to soluble fibrinogen. 
 
Fibrinogen is a protein of about 340 kDa with six polypeptide chains (two α, two β 
and two γ chains) linked by 29 disulfide bonds within the central domain of the 
molecule (9, 10). Fibrinogen contains two RGD motifs on the α−chain at positions 
95-97 and 572-574 that are important in the adhesion and aggregation interactions 
with the αIIbβ3 integrin (11-13). The terminal 12 amino acids on the C-terminus of the 
γ-chain (HHLGGAKQAGDV) contain the fibrinogen-specific AGDV motif (at 
positions 408-411), which is also crucially involved in the initial interaction of αIIbβ3 
with fibrinogen (14-16). It is perhaps not surprising that additional adhesion motifs 
could be involved due to the complex nature of these interactions, involving 
conformational changes occurring within the integrin and fibrinogen. Evidence of this 
is suggested by the presence of residual adhesion to recombinant fibrinogen mutants 
lacking both the RGD and γ-chain dodecapeptide adhesion motifs (13, 17-19) and the 
ability of residues 365-383 on the γ-chain (which contains neither the RGD nor the 
AGDV integrin recognition motif) to support platelet adhesion and play a role in clot 
retraction (20, 21).  
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These data have led to the hypothesis that other fibrinogen sequences may play a role 
in the complex interaction with αIIbβ3. One potential binding motif in fibrinogen is 
Asn-Gly-Arg (NGR) which was originally reported by Koivunen et al. (22) as an 
α5β1-binding motif and later confirmed by phage display to be an integrin-recognition 
motif in fibronectin that interacts with both αVβ5 and αVβ3 (22-24). A cyclic NGR 
peptide (CNGRC) has also been characterized as a ligand for CD13 (aminopeptidase 
N), a membrane-spanning surface protein of 140 kDa, not found on platelets (25). 
NGR-containing peptides have been developed to aid in anti-tumor drug delivery to 
the tumor neovasculature (26, 27). Furthermore, NGR-containing peptides have also 
been used to target the endothelium with viral peptides (28). We investigated the 
possibility that the NGR-motif may bind to the integrin αIIbβ3 (the closest relative of 
αVβ3) since the NGR motif is found on the D-domain of fibrinogen (once on each β 
and γ fibrinogen chain at positions β413-415 and γ254-256 (Fig 1)). Importantly, the γ-
chain NGR is exposed on the surface of the molecule unlike the β-chain sequence, 
which is embedded within the fibrinogen structure in the D fragment.  
 
In this paper we explore the potential role of fibrinogen NGR sequences to mediate 
both platelet adhesion and platelet activation using site-directed mutagenesis of the 
NGR sequences in recombinant fibrinogen. 
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Methods 
 
Peptide synthesis 
Peptides were generated by standard solid-phase peptide synthesis (29). The NGR 
peptide sequences used were: CNGRCVSGCAGRC-NH2 (NGR-4C) and 
GCRVRCGSGCNCA-NH2 (scrambled peptide); CVLNGRMEC-NH2 (NGR-2C) and 
modified peptides with cysteine replaced with methionine (MNGRMVSGMAGRM-
NH2 (NGR-4M) and MVLNGRMEM-NH2 (NGR-2M)) which are equipotent, linear 
peptides that are less susceptible to multimerization. The β-chain (ANPNGRYYW) 
and γ-chain (EDWNGRTST) 9-mer sequences were also synthesized. 
 
Platelet Preparation 
The RCSI research ethics committee approved this study. Healthy volunteers, free 
from non-steroidal anti-inflammatory drugs for the previous 14 days donated blood. 
Platelet-rich plasma (PRP) and gel-filtered platelets were prepared as previously 
described (30). 
 
Platelet aggregation 
Platelet aggregation was performed as previously described (31). Inhibitors were 
incubated with PRP for 5 minutes or NGR peptides for 30 minutes prior to activation 
with 20 µM TRAP. 
 
Static platelet adhesion assay 
Cell adhesion was performed as previously described (32) using microtitre plates that 
were coated with different fibrinogens (20 µg/ml) overnight at 4°C and blocked with 
1% bovine serum albumin (BSA). Gel-filtered platelets were incubated with peptides 
or antagonist at 37°C for 30 minutes or activated with 10 µM thrombin receptor 
activating peptide (TRAP) for 37°C for 5 minutes and before addition to the plate.  
 
Preparation of flow chambers 
Preparation of flow chambers was adapted from Kerrigan et al (33). Briefly 100 μl of 
purified fibrinogen (Calbiochem) or mutated fibrinogen at 50 μg/ml was applied to 75 
mm x 25 mm glass coverslips (Bellco Glass, New Jersey, USA) and incubated 
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overnight at 4°C or for 2 h at 37°C in a humidity chamber. After washing, coverslips 
were blocked for 1 h at 37°C with 1% (w/v) BSA in PBS.  
 
Epi-fluorescent microscopy 
Platelet interactions with immobilized proteins under shear were assessed using a 
parallel flow chamber (Glycotech, Maryland, USA) as previously described (33). 
Protein-coated coverslips were mounted on the vacuum chamber and washed 
thoroughly by aspirating 3 ml of PBS through the chamber using a syringe pump 
(Harvard Biosciences). Whole blood was incubated for 10 min at RT with the 
fluorescent dye DiOC6 (1 μM) and then flowed at 200 s-1 over the immobilized 
protein. Adherent platelets were visualized using fluorescent microscopy (Axio 
Observer Z1 Microscope, Plan-Apochromat 63x/1.40 Oil DIC objective lens and a 
GFP filter) and processed using Zeiss Axiovision 4.7 software. Images were taken in 
the centre of the chamber downstream of the flow entrance at 0 s 100 s, 200 s and 300 
s and the number of adherent platelets quantified per field of view for 3-5 independent 
experiments.  
 
Precipitation  of NGR-associated proteins. 
Gel filtered platelets were incubated with 150 µM biotinylated NGR or biotinylated 
scrambled peptide for 15 minutes at room temperature. The platelets were washed 
with platelet buffer, resuspended and then subjected to chemical cross-linking. Cross-
linking with the homobifunctional N-hydroxysuccimide cross-linker 
dithiobissuccinimidyl propionate (DSP) was performed as described previously (34). 
In brief, platelets were treated at 4°C for 30 minutes with 100µg DSP per mg protein. 
Cross-linking was terminated by the addition of a lysis buffer (final concentration: 1% 
Triton X-100; 50mM Tris pH 7.4; 150 mM NaCl, 2 mM EDTA; 1 mM pefabloc; 1 
mM antipain; 1 mM pepstatin; 1 mM E64; 1 mM chymostatin; 1 mM leupeptin; 1 
mM benzamide and 1 mM trypsin inhibitor) followed by incubation with 
Neutravidin beads for 1 hour. The bound proteins were eluted using reducing buffer 
containing 75 mM dithiothreitol (DTT) at 37°C for 15 minutes. The samples were 
separated on a 7% polyacrylamide gel and immunoblot analysis was performed using 
CD41 primary antibody (clone SZ22, Imunotech) diluted 1:1000 in blot buffer, 
followed by secondary HRP-conjugated antibody (1:10000 dilution) and visualization 
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of reactive proteins was by enhanced chemiluminescence (Super Signal, Pierce, IL, 
USA). 
 
 
Mutagenesis of fibrinogen plasmids  
The Arg-Gly-Asn (NGR) on either the β-chain or γ-chain plasmid vectors of 
fibrinogen were mutated to Ala-Ala-Ala (AAA) using the Transformer TM Site-
directed Mutagenesis kit (BD Biosciences), based on method of Deng et al (35). The 
plasmids containing the cDNA’s of all three fibrinogen chains has been previously 
described (36). The NGR to AAA change in the β -chain cDNA plasmid (p668) was 
introduced using primer βNGR to AAA (P-5’-GCAGCCAATCCAG 
CCGCCGCATACTACTGGGGTG-3’). The Hind III recognition sequence was 
altered using the primer Selection Hind (5’-TCTAGGGCCAGGCTTGTTTGC-3’).  
The NGR to AAA change in the γ -chain cDNA plasmid (p674-2) was introduced 
using primer γ-NGR-AAA_F (P-5’-GAACTGGAAGACTGGGCTGCCGCAACC-
AGTACTGCAGACTATGCC -3’). The Hind III recognition sequence was altered 
using the primer Selection Hind (5’-TCTAGGGCC AGGCTTGTTTGC-3’). Primers 
were made by Sigma Aldrich. All primers are phosphorylated at the 5’ end. T4 DNA 
polymerase was used to anneal mutated plasmids to denatured p668 or p674-2 and 
ends were joined with T4 DNA ligase. Hind III (New England BioLabs) incorporation 
allowed for selective digestion of the mutant plasmids and MutS Escherichia coli 
were subsequently transformed. Plasmid DNA was isolated using QIAprep® Spin 
Miniprep kit (QIAGEN) and sequenced using ABI Prism® BigdyeTM Terminator 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems).  
 
Recombinant fibrinogen synthesis and purification 
Recombinant fibrinogen was synthesized as previously described (36) using Chinese 
hamster ovary (CHO) cells expressing the α-chain and either the β-chain or the γ-
chain of fibrinogen (kind gift from S. Lord) (37). The mutated plasmids, p668 
(containing β -chain cDNA) and p674-2 (containing γ -chain cDNA) were transfected 
into CHO cells expressing the other appropriate fibrinogen chains. The clones with 
the highest fibrinogen secretion as determined by an enzyme-linked immunosorbent 
assay (ELISA) were selected. Cells were grown in serum-free conditions (using 
insulin-transferrin-selenite supplemented media) and in roller bottles to maximize 
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harvest. Protease inhibitors were added to harvested media and stored at -20°C until 
protein purification. The fibrinogen was subsequently purified by ammonium sulphate 
precipitation followed by affinity chromatography using an anti-fibrinogen antibody 
as previously described (36). The purified fibrinogens were dialyzed extensively 
against 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), pH 
7.4, 150 mM NaCl, concentration determined by ELISA and stored at -20°C. Purity 
was determined by running samples (10 µg) on 10% SDS-PAGE gels under reduced 
and non-reducing conditions. Fibrinogen was polymerized with thrombin (1U/ml) in a 
buffer containing CaCl2, the clot was removed and the protein concentration 
remaining was determined by the Bradford method.  
 
Transfection of αIIbβ3 into COS cells 
COS cells were transiently co-transfected with pcDNA3-αIIb and pcDNA-β3. 
Unligated pcDNA was used for mock controls. When the cells were between 50-80% 
confluent, 9 µg of pcDNA-αIIb and pcDNA-β3 were mixed with 60 µl of 
lipofectamine and 1.6 ml Optimen for 15 minutes in the dark. This transfection 
mixture was added to the COS cells and incubated at 37°C with 5% CO2 for 5 hours. 
After the addition of fresh media the cells were harvested at 60 hours.  
 
Enzyme Linked Immunosorbant Assay for fibrinogen detection 
Plates (Nunc maxisorb) were coated with 100 µl of sample for 2 hours, washed with 
0.01% Tween 20 in PBS (PBST), blocked with 1% BSA for 2 hours, all at 37°C. 
Primary rabbit anti-human fibrinogen (50 ng/ml) (Merck Biosciences, Darmstadt, 
Germany) was added for 1.5 hours, washed (PBST) and secondary peroxidase 
conjugated goat anti-rabbit IgG antibody (100 ng/ml) (Pierce) was added for 1 hour, 
all at 37°C. Plates were washed (PBST) before addition of peroxidase substrate and 
read at absorbance 405 nm. A standard curve of commercial fibrinogen (Calbiochem, 
Darmstadt, Germany) was prepared with a range between 0.1-20 µg/ml. The ELISA 
allowed the quantification and detection of fibrinogen expression in samples from cell 
culture. 
 
Confocal microscopy 
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Fibrinogens (20 µg/ml) or TBS (control) were coated onto clean poly-L-lysine slides 
for 2 hours at 37°C or overnight at 4°C. The slides were blocked at 37°C for 2 hours 
with 1% BSA in TBS, rinsed and coated with gel-filtered platelets (3x107 
platelets/ml) at 37°C for up to 1 hour. In some experiments adhered platelets were 
fixed with 3.8% paraformaldehyde for 10 minutes. Glass cover slips were applied and 
slides viewed with an oil-immersion 63X objective lens in Differential Interference 
Contrast (DIC) with a Zeiss LSM 510 confocal microscope. Alternatively, non-fixed 
samples were stained for F-actin using Alexa 546 phalloidin (Molecular probes) and 
CD41 (clone P2, Beckman Coulter) and secondary Alexa 488 (Molecular probes). For 
real time imaging, the slides were mounted on a 37°C preheated stage and a 63X 
water immersion lens was used to view platelet spreading every 2 minutes for 45 
minutes.  
 
There are three distinct categories of phenotypic changes seen over time with platelets 
adhering to fibrinogen. Firstly, quiescent, circulating platelets are typically round, 
with no pseudopodia (finger-like projections/extensions) when they initially bind 
(Fig. 2A). Secondly, as a result of the interaction between immobilized fibrinogen and 
the resting integrin αIIbβ3, filopodia are produced (these appear as spikes and 
correspond to a partially activated platelet), this is followed by ‘outside-in’ signaling 
resulting in lamellipodia formation (the further extension of the platelet to ‘fill in’ the 
gaps between the filopodia) (38) (Fig. 2B). Finally, the platelet becomes fully spread, 
adopting the typical fried egg shape (with the point of contact constituting the ‘yolk’) 
(Fig. 2C). This larger round disk shape reflects the full activation of the platelet. 
These three morphological types are designated 1) round or resting, 2) spiked and 3) 
spread, as previously described (39, 40) 
 
To analyse the percentage of platelets spread or activated, we randomly selected three 
to five fields of view from nine separate experiments, accounting for 800-1000 
platelets in total. The percentage of platelets spread or activated was calculated as a 
fraction of total platelets. 
 
GPIIb/IIIa receptor occupancy assay. Binding of NGR peptides to αIIbβ3 was 
determined using a flow cytometric assay (GPIIb/IIIa receptor occupancy kit) from 
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BioCytex, Marseille, France. This assay measures the ability of αIIbβ3 antagonists to 
inhibit the binding of two anti-αIIbβ3 antibodies (Mab 1 and Mab 2) (41, 42). The 
assay was performed according to the manufacturers instructions. 
 
Clot retraction assay 
PRP (400 µl) was mixed with 50 µl of drug and incubated at 37°C for 30 minutes 
unstirred. Human α thrombin was added at a final concentration of 1 U/ml and 
incubated at 37°C for a further 20 minutes unstirred. Clot retraction was determined 
by weighing the volume of fluid remaining after 20 minutes. Parallel experiments 
were performed in the absence and presence of abciximab (10 µg/ml), which prevents 
clot retraction. Data are expressed as a percentage of the abciximab result. 
 
Docking studies. Docking was carried out using AutoDock Vina (43) with the default 
parameters (9 binding modes, a maximum exhaustiveness of 8, and maximum energy 
difference of 3 kcal/mol). The NGR peptides were generated using Molecular 
Operating Environment (MOE; Chemical Computing Group Inc., Montreal, Quebec, 
Canada) with N-terminal acetylation and C-terminal amidation. The figures were also 
generated using MOE. (44) 
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Results  
 
The effect of NGR-peptides on platelet function 
To determine if NGR can bind to αIIbβ3 we investigated the ability of the previously 
described synthetic NGR-containing peptide (CNGRCVSGCAGRC (NGR-4C)) (24, 
45) to inhibit αIIbβ3-dependent platelet functions including adhesion to fibrinogen, 
aggregation and clot retraction. Resting platelets strongly adhered to fibrinogen and 
adhesion was inhibited by the NGR peptide (IC50 of 175 µM, n=3), the RGDS peptide 
(IC50 of 5 mM, n=3) and by the specific αIIbβ3 antagonist, eptifibatide (IC50 of 0.125 
µM, n=3) (Figure 3a). In contrast, an antibody to αVβ3 (LM609, 20 µg/ml) had no 
effect on adhesion (platelets adhered 98.7±2 % of control). Activation of platelets 
prior to adhesion abolished the inhibitory effect of NGR (500 µM: activated 92±15 % 
vs 23±4 % in non-activated platelets, compared with their respective no drug controls, 
n=3, p<0.05) while activation of platelets had no effect on inhibition by RGDS (data 
not shown). In contrast to the effect on adhesion, the NGR peptide (500 µM) failed to 
inhibit either platelet aggregation (24 ± 2 % inhibition, n=3, p<0.005) (Figure 3b) or 
clot retraction (9±7 % inhibition, n=3, p=NS) (Figure 3c) while RGDS (500 µM) and 
eptifibatide (100 µM) inhibited platelet aggregation (76±13 % inhibition and 100±0 
%, respectively, n=3, p<0.005) and clot retraction (95±6 % and 100 ± 6 % inhibition, 
n=3, p<0.0001 respectively).  
 
The role of NGR in platelet adhesion. 
To confirm that the NGR motif is involved in platelet adhesion we investigated the 
ability of platelets to adhere to a surface coated with biotinylated NGR-4M peptide 
(Biotin-MNGRMVSGMAGRM-NH2) and by observing the morphology of the 
adhered platelets. Platelets adhered to the NGR-coated surface at a level of 67% 
compared to a fibrinogen-coated surface. Adhesion to NGR was inhibited by both the 
NGR-2M peptide (89.4±5.5% inhibition, n=3, P=0.0003) and the RGD peptide 
(89.0±4.4% inhibition n=3, P=0.0002) (see Figure 4d). Furthermore, we investigated 
the morphology of platelets after adhering to poly-L-lysine (Figure 4a), fibrinogen 
(Figure 4b) or immobilized NGR-4C (Figure 4c) as determined by DIC microscopy. 
Platelets appeared rounded on poly-L-lysine but adopted the classic flat profile of 
 12
spread platelets on fibrinogen. On immobilized NGR, platelets showed pseudopod 
formation (finger-like projections/extensions) typically seen in activated platelets, but 
did not spread fully. To determine if NGR is a ligand for αIIbβ3 we investigated the 
binding of NGR-4C to HEL cells, an erythroleukemia cell line expressing αIIbβ3 (46) 
and COS cells transfected with αIIbβ3. A fluorescently-labelled NGR peptide was 
found to bind to both HEL and transfected COS cells and to partially co-localize with 
αIIbβ3 but failed to bind to mock-transfected COS cells (Figure 5). To further confirm 
the ability of NGR to bind to αIIbβ3 we cross-linked biotin-NGR peptide to platelets, 
precipitated the peptide with Neutravidin. A Western blot of the the precipitate 
showed the presence of αIIb (Figure 5j). 
 
Effect of β-chain NGR on platelet secretion 
TRAP (20 µM) induced PAC-1 binding (36±5% positive platelets) and P-selectin 
expression (53±8% positive platelets) in platelets. The β-chain NGR peptide also 
induced PAC-1 binding (26±3% positive platelets) and P-selectin (28±5% positive 
platelets) although to a lesser extent. However, when added to PRP NGR-2M failed to 
induce platelet aggregation (4±1% aggregation). 
 
αIIbβ3 receptor occupancy 
Mab 1 binding to platelets was strongly inhibited by abciximab (10 µg/ml, P<0.001) 
while MAb 2 binding was inhibited by tirofiban (320 nM, P<0.001). NGR-2M (500 
µM) reduced the binding to platelets of Mab 1 by 5,926±2,012 and Mab 2 by 
1,028±770 although neither were significant (P>0.05). 
 
Recombinant fibrinogen 
To determine if the NGR sequences in fibrinogen actually play a role in the 
interaction with αIIbβ3 we generated recombinant, wild type fibrinogen (rFg) as well 
as fibrinogen where the NGR sequences in the β chain (Fgβ-) and the γ chain (Fgγ-) 
were replaced with three alanines. These recombinant fibrinogens were of very high 
purity equivalent to that of commercially available purified plasma fibrinogen (Figure 
6). To determine the functionality of the recombinant fibrinogens the percentage of 
protein that was clottable was determined. Commercial, purified, plasma fibrinogen 
was 70.2% ± 5 (SD, n=3) clottable and the recombinant fibrinogens (rFg: 72.3% ± 7; 
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Fgβ-: 72.6% ± 10; Fgγ-: 47.8% ± 27) were not statistically different (ANOVA: 
P=0.2). 
 
Resting platelets adhered to purified recombinant fibrinogen (rFg) and plasma 
fibrinogen (pFg) to the same extent (rFg 102.4 ± 5.5 % compared to pFg, paired 
student t-test, NS, n=3), however, platelet adhesion to both Fgβ- and Fgγ- were 
significantly reduced (Fgβ-: 38.7±11.9 % P<0.01, n=14 and Fgγ-: 44.3±16.4 % 
P<0.05, n=14 reduction compared to pFg, paired-t-test) (Figure 7). In addition, 
platelets failed to adhere to immobilized Fgβ- and Fgγ- compared to fibrinogen 
control, when perfused at 200 s-1 (Figure 8, P<0.0001, n=3-5). 
 
The role of NGR in platelet spreading 
The ability of platelets to spread on immobilized NGR peptides suggest that the NGR-
sequence may play a role in triggering platelet spreading. To confirm this we studied 
the phenotype of platelets after adhesion to the recombinant fibrinogens. Consistent 
with previous results, platelets failed to spread on BSA, but spread extensively on 
immobilized plasma fibrinogen. The percentage of adherent platelets that spread was 
significantly reduced on both Fgβ- (16.1±7.4 % of total platelets spread) and Fgγ- 
(27.6±11.4 % of total platelets spread) compared to control plasma fibrinogen 
(55.1±9.5 % of total platelets spread) (One way ANOVA, P=0.005, n=8) (Figure 8a & 
b). However, activation of platelets with thrombin receptor-activating peptide (TRAP) 
for 5 minutes prior to adhesion resulted in a similar number of fully spread platelets 
adhered to Fgβ- compared to plasma fibrinogen (50.8±3.6 % vs 64.2±5.2 % for Fgβ- 
and plasma fibrinogen, respectively, n=5, P=0.08) (Figure 8c). The number of spread 
platelets was attenuated for Fgγ- (41.4±2.4 % after TRAP activation compared to the 
control for pre-activated platelets, n=5, P=0.004). Thus, when either NGR peptide is 
deleted from fibrinogen there is a significant reduction in both numbers of adhered 
platelets as well as the extent of spreading of resting platelets while activated platelets 
are unaffected. 
 
To further characterize the role of the NGR sequence on platelet morphology we 
investigated the kinetics of platelet spreading on fibrinogen by imaging platelets every 
two minutes for 45-minutes. The number of spiked platelets on each fibrinogen 
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appeared similar, peaking at approximately fifteen minutes, however at 35-minutes 
the number of spiked platelets on plasma fibrinogen was decreased compared to each 
mutant (data not shown) corresponding to an increase in fully-spread platelets on 
plasma fibrinogen. As well as reduced levels of spreading the rate of transition from 
spiked to spread was slower for the mutants. The time taken for platelets to fully 
spread, as defined by no further evidence of lamellipodia formation or increase in 
surface area coverage of each individual platelet, was similar between plasma 
fibrinogen and the Fgγ- (13.9±1.1 min vs 15.7±1.3 min, respectively, n=3, P=0.274). 
However, the time taken for platelets to spread on Fgβ- was significantly slower 
(20±2.5 min, n=3, P=0.013) (Figure 8d). Interestingly, pre-activation of platelets with 
TRAP induced a similar rate of spreading between plasma fibrinogen and Fgβ- 
(12.7±0.8 min and 13.8±1.0, respectively, n=3, P=0.378), whereas the Fgγ- spread 
more rapidly than either (9.1±0.7 min, n=3, P=0.002).  
 
Docking studies 
To try and better understand the different effects of NGR-containing peptides we 
generated models of the binding mode of the peptides to the resting and activated 
crystal structures of αIIbβ3 (Figure 9). We docked the NGR tri-peptide and RGDS in a 
form that was acetylated and amidated to avoid interactions with the N and C-termini. 
These docking poses were then compared to 9-mer peptides from the β and γ chains 
of fibrinogen as well as to a phage-derived NGR-2C peptide (see Table 1). The NGR 
tri-peptide was predicted to bind in a pose analogous to RGDS peptide. The NGR and 
RGDS peptides also mimic the crystal structure poses of the RGD analogues where 
the compounds bridge the space between the D224 of the α-chain and the Mg2+ ion 
associated with the β-chain I-domain. The longer peptides appear to be affected by 
their flanking amino acids and do not adopt the same position. None of the 9-mer 
peptides were predicted to bind with the NGR bridging directly between the D224 and 
the magnesium ion. There does not appear to be a pattern for binding for the NGR 
sequence among the 9-mer peptides. They do all fit into the pocket and are predicted 
to bind with reasonable docking energies that are comparable with RGDS (Table 1). 
The peptide with the highest affinity is the β-chain NGR sequence binding to the 
resting receptor. All peptides except the β-chain NGR had higher affinities for the 
activated receptor. In the full-length fibrinogen molecule, the residues flanking the 
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NGR may be more constrained than in our peptides and therefore in the full-length 
fibrinogen, they may be unable to interact as extensively with the pocket.  
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Discussion 
 
αIIbβ3 plays a critical role in platelet function due to its ability to bind to fibrinogen. 
Like many integrins activation of αIIbβ3 by a process known as inside-out signaling is 
necessary for fibrinogen binding (4, 5). This binding occurs through the fibrinogen 
RGD (11-13) and γ-chain dodecapeptide sequences (14, 15). However, resting αIIbβ3 
is capable of binding to immobilized fibrinogen in a mechanism that appears to be 
independent of both the RGD and γ-chain dodecapatide sequences (13, 17-19). This 
binding also leads to an activation of the platelet in a process known as outside-in 
signaling (7, 8). The NGR sequence was identified as an integrin-binding motif and is 
known to bind to α5β1 and αVβ3 (22-24). While both α5β1 and αVβ3 are present on the 
platelet surface they are present at very low levels and platelet adhesion to fibrinogen 
was not inhibited by the anti-αVβ3 antibody LM609 (unpublished data). Similarly 
Staphylococcus aureus expressing a fibronecting-binding protein can support platelet 
adhesion and aggregation in the presence of fibronectin but only in an αIIbβ3-
dependent
 
manner (47). Also, platelet adhesion to fibrinogen is completely blocked by 
specific αIIbβ3 antagonists and not by other anti-platelet agents (32). Thus, it is 
unlikely that NGR could inhibit platelet adhesion to fibrinogen by an interaction with 
either α5β1 or αVβ3. However, as αVβ3 is closely related to αIIbβ3, both are fibrinogen 
receptors and fibrinogen contains the NGR sequence we investigated the potential for 
NGR to act as an αIIbβ3 binding motif. 
 
An NGR-containing peptide had no effect on either platelet aggregation or clot 
retraction in contrast to the RGD peptide. However, the NGR-containing peptide was 
nearly 30-times more potent than RGDS at inhibiting resting platelet adhesion to 
immobilized fibrinogen; although, when platelets were pre-activated the NGR-
containing peptide failed to inhibit platelet adhesion to fibrinogen. Thus, NGR only 
blocks fibrinogen binding to resting platelets. This was confirmed to be due to direct 
binding of NGR to αIIbβ3 as shown be the ability of NGR peptides to only bind to 
COS cells when transfected with αIIbβ3 and by the abiity of biotinylated-NGR to pull 
down αIIb when incubated with platelets. 
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While NGR peptides are capable of blocking fibrinogen binding to αIIbβ3 this does 
not mean that the NGR sequences in fibrinogen are available to bind to αIIbβ3. 
However, replacement of either NGR sequence with AAA resulted in approximately 
40% reduction in platelet adhesion. This is not due to the nature of the recombinant 
proteins as recombinant wild-type fibrinogen supports adhesion to a similar extent as 
plasma fibrinogen. As blood continually flows through the blood vessels platelets are 
exposed to a range of shear conditions that have a significant effect on their function. 
Under shear conditions platelets failed to adhere to immobilized mutant fibrinogens 
although they did adhere to wild-type fibrinogen. Thus, both NGR sequences appear 
to play a role in the interaction with αIIbβ3 under both static and shear conditions. 
 
It is well established through crystallization studies that RGD peptides and peptide 
mimetics bind with the same general mechanism to αIIbβ3 (16, 46, 47). Firstly there is 
a strong interaction between the side chain of the arginine of the peptide and the D224 
on the β propeller of the αIIb subunit. The second interaction takes place between the 
acidic side chain of the aspartic acid in the RGD peptide and the MIDAS Mg2+ ion in 
αIIbβ3. While the NGR-trimer does not contain an acidic group, and our docking 
predicts that it does not interact with the Mg2+ ion, it does lie between the two 
domains spanning the entire pocket (Figure 9). The arginine is predicted to form a 
hydrogen bond with the D224 in both the resting and activated receptor. Having said 
this, its predicted docking energies are analogous to the RGDS docking result. Many 
of the αIIbβ3 receptor antagonists partially activate the receptor (48). NGR is able to 
bind to the resting receptor and it also activates the receptor. Activation of αIIbβ3 
appears to be dependent on contact between the ligand and the MIDAS domain and 
the β3 subunit (47). While NGR does not make direct contact with the Mg2+ ion, it is 
predicted to form hydrogen bonds with β-chain residues. Docking studies of the 9-
mer peptides derived from the fibrinogen β and γ chains suggested that the β-chain 
NGR-peptide has a stronger affinity for the RGD binding site on resting αIIbβ3. The 9-
mers have more rotatable bonds than the trimer and are not constrained. There 
appears to be no consistency as to how these peptides docked into αIIbβ3. They were 
however all able to bind to the ligand-binding site with comparable docking energies. 
In the fibrinogen macromolecule, the γ-chain NGR is exposed and the β-chain 
sequence is buried (Figure 1) suggesting that conformational changes may occur on 
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immobilization of fibrinogen that expose the β-chain NGR. It is unlikely that the full 
9 amino acids that we modeled would be exposed and even if they were, they would 
be constrained. Therefore, while it is interesting to look at the 9-mers, it is probably 
more realistic to draw conclusions from the trimer modeling results. In conclusion, 
the NGR sequence is predicted to bind to αIIbβ3 in a similar manner to RGD and the 
RGD analaogues. The trimer is predicted to form a hydrogen bond with the D224 of 
αIIbβ3, however, it is not predicted to interact with the magnesium directly. It does 
however, make contact with the β I-domain providing a possible mechanism for 
activation. All of the 9-mer peptides interacted with residues on the β-chain I-domain. 
Movement in the β-I domain in response to ligand binding is responsible for 
activation of αIIbβ3 (16, 48-50). Thus, the differences in activity of the peptides does 
not appear to be due to differences in binding ability (potency) and is likely due to 
differences in efficacy. 
 
The ability of platelets to spread on immobilized NGR peptide suggests that the role 
of NGR is not confined to facilitating adhesion; it also mediates outside-in signaling 
(38). This was confirmed by the reduction in platelet spreading by 50-70% for the 
mutant fibrinogens. Further analysis showed that this was due to an increase in the 
number of resting platelets with the number of spiked platelets remaining the same 
and a decrease in fully spread platelets. Thus, in the absence of NGR platelets fail to 
become activated. However, when activated with TRAP platelets spread normally 
with the mutant fibrinogens. Furthermore, when platelets did spread the rate of 
spreading as measured by the average time to being fully spread was similar for both 
wild type and γ-chain-deficient fibrinogens at around 15 min, which was similar to 
that with TRAP-activated platelets. However, the time to full spreading on β-chain 
fibrinogen deficient in NGR was 20 min but the time to spreading of TRAP-activated 
platelets was unaffected. The effects of PAR-mediated platelet activation on 
spreading are consistent with that seen with mouse platelets (40). 
 
Interestingly, with the fibrinogen lacking the γ-chain NGR sequence the extent of 
spreading with TRAP-activated platelets was less than that with wild-type fibrinogen 
but the time to spreading was significantly shorter. This could potentially be due to a 
knock-on effect of the mutation on the exposure of the γ-chain dodecapeptide that 
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could alter its ability to interact with αIIbβ3. It could also suggest that there may be 
differences in the interaction of the β- and γ-chain NGR sequences from fibrinogen 
with αIIbβ3. The β-chain peptide has strong platelet activating effects and the β-chain 
mutant has significantly reduced levels of adhesion suggesting that it plays a key role 
in activation.  
 
These data suggest that when fibrinogen adheres to a surface there is a conformational 
change (51, 52) potentially leading to exposure of the NGR sequences in both the β- 
and γ-chains. A recent study has confirmed that the interaction of αIIbβ3 with soluble 
fibrinogen is different to that for immobilized fibrin(ogen) (53). αIIbβ3 is known to 
exist in different conformations (54) and NGR sequences bind to a conformation 
associated with resting platelets and play an important role in generating the 
intracellular signal that mediates the initial platelet spreading. The NGR sequence 
appears to facilitate the initial capture of flowing platelets. The subsequent activation 
of αIIbβ3 allows firmer adhesion through the RGD and γ-chain dodecapeptide 
sequences. Thus, the interaction of NGR with αIIbβ3 may be analogous to the vWf 
interaction with GPIbα as both facilitate the capture of flowing platelets to substrate 
immobilized on a surface. Interestingly galectin-1 has been shown to be a ligand for 
αIIbβ3 and induces platelet spreading even though it does not contain the RGD or 
AGDV sequences however, it does contain an NPR motif (55). It is also known that 
some small molecule αIIbβ3 antagonists have differential affinity for resting and 
activated αIIbβ3. Thus, antagonists with higher affinity for resting αIIbβ3 may have 
more in common with NGR than RGD (56, 57). Future work will include producing a 
mutant fibrinogen lacking the NGR, RGD and γ-chain dodecapeptide sequences, 
which should be unable to support either platelet adhesion or aggregation. 
 
Once inserted central venous catheters (CVC) are rapidly coated in fibrinogen. 
Subsequently resting platelets can bind to the immobilized fibrinogen leading to the 
formation of a thrombus (catheter-related thrombosis; CRT). At best this requires the 
replacement of the CVC but embolism can lead to many complications including 
serious events such as pulmonary embolism. It is estimated that at least 10% of all 
cases of venous thromboembolism are due to CRT and that approximately 20% of all 
CVCs show evidence of CRT (58). In addition to CRT catheters can also become 
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infected and a recent meta-analysis estimates the incidence to be approximately 1 per 
1,000 catheter days (59). Staphylococcus aureus is one of the bacteria that is often 
implicated in catheter-related infections (60) and this can progress to serious 
conditions such as septicemia and infective endocarditis. S. aureus express numerous 
fibrinogen-binding proteins and these can bind to the fibrinogen-coated catheters. 
However, these fibrinogen-coated bacteria subsequently recruit resting platelets 
leading to platelet activation and thrombus formation (47, 61, 62) and clumping factor 
A has been found to be the most important one especially under shear conditions (33). 
An NGR analogue has the potential to prevent the binding of resting platelets to 
fibrinogen-coated catheters without affecting activated platelets. This would prevent 
CRT without causing bleeding problems. These compounds would also have the 
potential to prevent S. aureus-mediated infective endocarditis again without 
increasing bleeding risk. 
 
Thus, NGR is a novel αIIbβ3 recognition sequence in fibrinogen that specifically 
interacts with resting αIIbβ3 mediating platelet activation and spreading.  
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Tables 
 
Peptide Sequence Docking energies (kcal/mol) 
  Resting Activated 
RGDS Ac-RGDS-Am -7.1 -8.1 
NGR-2C Ac-CVLNGRMEC-Am -7.7 -8.0 
Beta-NGR Ac-ANPNGRYYW-Am -8.6 -8.1 
Gamma-NGR Ac-EDWNGRTST-Am -6.8 -7.5 
NGR  Ac-NGR-Am -7.2 -7.6 
 
 
Table 1. The predicted docking energies for RGDS and the NGR peptides using both 
resting (PDB 3NIF) and activated (PDB 3FCU) conformations of αIIbβ3 using 
AutoDock Vina. 
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Figure Legends 
 
Figure 1: Crystal Structure of human fibrinogen D- fragment with positions of 
NGR residues highlighted. The α-chain is coloured blue, the β-chain green and the 
γ-chain red. Asparagine-Glycine-Arginine residues are displayed as space-fill. The 
crystal structure used was PDB 3NIF. 
 
Figure 2. Spreading phenotype stages in platelets adhering to fibrinogen. Gel-
filtered platelets were allowed to adhere to plasma fibrinogen for 45 minutes. Platelets 
were fixed with 3.8% paraformaldehyde and stained for F-actin with phalloidin Alexa 
546nm (red) and for αIIbβ3 with CD41 antibody (green). A) Round resting platelets, 
B) partially activated, spiked platelets, C) spread platelet. Images are representative of 
the larger data set. 
 
Figure 3.  NGR peptide inhibits platelet adhesion but has no affect on platelet 
aggregation or clot retraction. A. Inhibition of adhesion of gel-filtered platelets to 
immobilized fibrinogen (20 µg/ml) by the αIIbβ3 antagonist eptifibatide (IC50 = 0.125 
µM) (), NGR peptide (IC50=175 µM) () and RDGS peptide (IC50=5 mM) (). B. 
Inhibition of ADP (20 µM) induced platelet aggregation by eptifibatide (IC50=0.4 
µM), NGR peptide (IC50 > 0.5 mM) and RDGS peptide (IC50=120 µM). C. Inhibition 
of thrombin (1U/ml) induced clot retraction by the αIIbβ3 antagonist eptifibatide 
(IC50=12.5 µM), NGR peptide (IC50>0.5 mM) and RDGS peptide (IC50=120 µM). All 
data are expressed as mean ± SD, n=3. 
 
Figure 4. Platelet adhesion to immobilized fibrinogen and NGR peptide. 
Morphology of adhered washed platelets to A. poly-L-Lysine, B. fibrinogen or C. 
immobilized NGR was observed using differential interference contrast microscopy. 
Note that platelets adherent to NGR become activated. D. Washed platelets were 
allowed to adhere to immobilized fibrinogen (20µg/ml) () or immobilized NGR 
peptide (20 µg/ml) (). This interaction was inhibited by the NGR (500 µM) and 
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RGDS (10 mM) peptides, data are expressed as percentage of platelet binding to 
fibrinogen control, ± SD, n=3. 
 
Figure 5. Binding of NGR peptide to integrin αIIbβ3. A-F represents HEL cells 
which express αIIbβ3 stained or treated with the following; A. CD41 only (red), B. 
biotinylated NGR only (green), C. CD41 and NGR, D. biotinylated scrambled NGR 
peptide, E. eptifibatide and F. anti-αvβ3 and NGR peptide. Note partial colocalization 
is evident in C but not D. G-I represents COS cells, G. mock transfected COS cells, 
stained for αIIbβ3 and NGR, H. DIC image of G and I. COS cells transfected with 
αIIbβ3, stained with CD41 and treated with NGR peptide, shows partial colocalization 
of CD41 and NGR. J. Platelets were incubated with biotinylated-NGR or biotinylated-
scrambled peptide and then cross-linked with dithiobissuccinimidyl propionate. The 
platelets were lysed in 1% Triton-X 100 and precipitated using Neutravidin beads. 
Precipitates were run on 7% gels and probed with the anti-αIIb monoclonal antibody, 
CD41. Lane 1, platelet lysate alone; lane 2, purified αIIbβ3; lane 3, platelets cross-
linked to biotinylated NGR, Neutravidin-precipitated; lane 4, platelets cross-linked to 
biotinylated scrambled peptide, and lane 5, Neutravidin-precipitation of cross-linked 
platelets without peptide. Blot representative of three independent experiments. 
 
Figure 6. Purity of recombinant fibrinogen. Purified and un-purified fibrinogen 
samples (10 µg) were run on 10 % 1D SDS-PAGE gels, A. under non-reducing 
conditions and stained with Coomassie blue or B. under reducing conditions and 
stained with silver stain. Samples used were commercially available, purified 
fibrinogen (Fg), recombinant wild type fibrinogen (rFg), recombinant fibrinogen with 
the β-chain NGR replaced by AAA (Fgβ-) and recombinant fibrinogen with the γ-
chain NGR replaced by AAA (Fgγ-). There is also a sample of the crude recombinant 
protein prior to purification. 
 
Figure 7. Platelet adhesion to fibrinogen under resting and shear conditions. A. 
Purified plasma fibrinogen (pFg), recombinant fibrinogen with the β-chain NGR 
replaced by AAA (Fgβ-) and recombinant fibrinogen with the γ-chain NGR replaced 
by AAA (Fgγ-) were immobilized on 96 well platelets. Washed platelets were allowed 
to adhere to the fibrinogen and the adhered platelets were quantified using a 
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chromogenic assay for acid phosphatase. The data are expressed as % adhesion 
compared with plasma fibrinogen (n=14 ± SD). B. Platelet interactions with 
immobilized proteins under shear were assessed using a parallel flow chamber. Whole 
blood was incubated for 10 min at RT with the fluorescent dye DiOC6 (1 µM) and 
then perfused at 200 s-1 over the immobilized fibrinogen. Fluorescent images were 
acquired (x63) using an argon laser at 488nm at 0 s, 100 s, 200 s and 300 s. C The 
percentage of platelets spread was randomly selected from 5 areas on the slide *: 
P<0.0001, n=3. 
 
Figure 8. Morphological characterization of platelet adhesion. A. Confocal 
microscopy analysis of resting platelets adhered to pFg and both recombinant NGR 
fibrinogens at 45 minutes post adhesion. Five random fields of view for each 
experiment were obtained and platelets were categorized into round (black), spiked 
(grey) and spread (white) phenotypes expressed as a percentage of total adherent 
platelets. B. Corresponding images from A, resting platelets were stained for F-actin 
with phalloidin (red) and αIIbβ3 with CD41 antibody (green) and visualized using a 
Zeiss Confocal Microscope, LSM 510 was used with an oil immersion lenses 63X, 
zoom 4X. C. Platelet morphology with activation with TRAP (10 µM) prior to 
adhesion. These data are representative of seven to nine separate experiments and 
averaging 800-1000 platelets per condition, ± s.e.m. D. Time taken for platelets to 
fully spread after initial contact with fibrinogen (fried egg shape with no further 
extension of the leading edge) at the end of 45 minute real time imaging were 
analyzed for resting platelets () and TRAP activated platelets () using n=20 
platelets for each condition ± s.e.m. *: P< 0.05 and **: P < 0.01. 
 
Figure 9: Prediction of the binding mode of the NGR peptides. The binding modes 
of the NGR peptides (See Table 1) were predicted using Autodock VINA. The 
peptides were prepared using MOE. The αIIbβ3 structures used for the docking were 
PDB 3NIF and 3FCU for the resting and activated respectively. The figures represent 
the surface of the binding site between the metal ion dependent adhesion site 
(MIDAS), and the Asp 224 residue on the beta propeller domain of the α-chain. The 
negatively charged surfaces are coloured red and the positive regions blue. The β-
chain NGR peptide is coloured cyan, the γ-chain NGR peptide is coloured magenta, 
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and the phage derived NGR-2C is coloured green. The NGR sequence in all of these 
peptides is highlighted in space fill. The magnesium ion in the MIDAS site is 
coloured pink and the calcium ion coloured grey. Asp 224 is labelled on the surface. 
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Figure 1: Crystal Structure of human fibrinogen D- fragment with positions of 
NGR residues highlighted.  
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Figure 2. Spreading phenotype stages in platelets adhering to fibrinogen.  
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Figure 3.  NGR peptide inhibits platelet adhesion but has no affect on platelet 
aggregation or clot retraction.  
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Figure 4. Platelet adhesion to immobilised fibrinogen and NGR peptide.  
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Figure 5. Binding of NGR peptide to integrin αIIbβ3. 
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Figure 6. Purity of recombinant fibrinogen.  
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Figure 7. Platelet adhesion to fibrinogen under 
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resting and shear conditions.
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Figure 8. Morphological characterisation of platelet adhesion to recombinant 
NGR fibrinogen.  
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Figure 9: Prediction of the binding mode of the NGR peptides.  
